Delayed onset of pulmonary hypertension associated with an appetite suppressant, mazindol: a case report.
The use of the appetite suppressant agents aminorex and fenfluramine derivatives has been reported as a risk factor for the development of pulmonary hypertension. A 29-year-old female developed pulmonary hypertension suspected to be due to an amphetamine-like appetite suppressant agent, mazindol ((+/-)-5-(p-chlorophenyl)-2,5-dihydro-3H-imidazo [2,1-a] isoindol-5-ol). She was admitted to Sapporo Medical University Hospital with dyspnea due to severe pulmonary hypertension. Twelve months prior to admission, she had taken mazindol continuously for a period of 10 weeks. As yet, her pulmonary hypertension has not completely improved. This is the first reported case of mazindol-associated pulmonary hypertension, which developed after a long latent interval, and it suggests that mazindol is also a risk factor for the development of pulmonary hypertension, making long-term follow-up necessary for patients taking this anorectic agent.
Hagiwara
M
M
Second Department of Internal Medicine, Sapporo Medical University School of Medicine, Japan.
Tsuchida
A
A
Hyakkoku
M
M
Nishizato
K
K
Asai
T
T
Nozawa
Y
Y
Tsuchihashi
K
K
Shimamoto
K
K
D000328:Adult; D000635:Aminorex / Q000009:adverse effects / Q000627:therapeutic use; D001067:Appetite Depressants / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000139:chemically induced* / Q000503:physiopathology; D008454:Mazindol / Q000009:adverse effects* / Q000627:therapeutic use; D013997:Time Factors
D001067:Appetite Depressants; D000635:Aminorex; D008454:Mazindol